Zhu Wenquan, Zhao Qinfu, Sun Changshan, Zhang Zhiwen, Jiang Tongying, Sun Jin, Li Yaping, Wang Siling
Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, PR China.
Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, PR China.
Mater Sci Eng C Mater Biol Appl. 2014 Jun 1;39:13-20. doi: 10.1016/j.msec.2014.02.035. Epub 2014 Feb 24.
The purposes of this investigation are to design mesoporous carbon (MC) with spherical pore channels and incorporate CEL to it for changing its needlelike crystal form and improving its dissolution and bioavailability. A series of solid-state characterization methods, such as SEM, TEM, DSC and XRD, were employed to systematically investigate the existing status of celecoxib (CEL) within the pore channels of MC. The pore size, pore volume and surface area of samples were characterized by nitrogen physical absorption. Gastric mucosa irritation test was carried out to evaluate the safety of mesoporous carbon as a drug carrier. Dissolution tests and in vivo pharmacokinetic studies were conducted to confirm the improvement in drug dissolution kinetics and oral bioavailability. Uptake experiments were conducted to investigate the mechanism of the improved oral bioavailability. The results of solid state characterization showed that MC was prepared successfully and CEL was incorporated into the mesoporous channels of the MC. The crystallinity of CEL in MC was affected by different loading methods, which involve evaporation method and melting method. The dissolution rate of CEL from MC was found to be significantly higher than that of pure CEL, which attributed to reduced crystallinity of CEL. The gastric mucosa irritation test indicated that the MC caused no harm to the stomach and produced a protective effect on the gastric mucosa. Uptake experiments indicated that MC enhanced the amount of CEL absorbed by Caco-2 cells. Moreover, oral bioavailability of CEL loaded within the MC was approximately 1.59-fold greater than that of commercial CEL. In conclusion, MC was a safe carrier to load water insoluble drug by controlling the crystallinity or crystal form with improvement in drug dissolution kinetics and oral bioavailability.
本研究的目的是设计具有球形孔道的介孔碳(MC),并将塞来昔布(CEL)掺入其中,以改变其针状晶体形态,提高其溶解度和生物利用度。采用扫描电子显微镜(SEM)、透射电子显微镜(TEM)、差示扫描量热法(DSC)和X射线衍射(XRD)等一系列固态表征方法,系统研究了塞来昔布(CEL)在MC孔道内的存在状态。通过氮气物理吸附对样品的孔径、孔体积和表面积进行了表征。进行胃黏膜刺激性试验以评估介孔碳作为药物载体的安全性。进行了溶出试验和体内药代动力学研究,以确认药物溶出动力学和口服生物利用度的改善。进行摄取实验以研究口服生物利用度提高的机制。固态表征结果表明,成功制备了MC,并且CEL被掺入到MC的介孔通道中。MC中CEL的结晶度受不同负载方法的影响,这些方法包括蒸发法和熔融法。发现CEL从MC中的溶出速率明显高于纯CEL,这归因于CEL结晶度的降低。胃黏膜刺激性试验表明,MC对胃没有损害,并且对胃黏膜产生保护作用。摄取实验表明,MC增加了Caco-2细胞吸收的CEL量。此外,负载在MC中的CEL的口服生物利用度比市售CEL大约高1.59倍。总之,MC是一种安全的载体,通过控制结晶度或晶体形态来负载水不溶性药物,同时改善药物溶出动力学和口服生物利用度。